Theravance Biopharma highlights YUPELRI growth, $250M buyback progress, and ampreloxetine Phase 3 start

Theravance Biopharma, Inc.

YUPELRI achieved all-time high net sales and profit in Q2 and Q3 2022; expects continued Q4 growth.
$250M capital return program ~50% completed as of 12/31/2022; ~$95M GSK buyback and ~$33M open market repurchases.
Ampreloxetine Phase 3 CYPRESS trial in MSA patients with nOH to start Q1 2023; orphan drug submission planned.
Targeting Non-GAAP profitability by 2H 2023; $50M milestone if TRELEGY sales reach ~$2.86B in 2023.
Sale of TRELEGY royalty interests for $1.1B upfront eliminated all debt; financial restructuring completed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.